Positive News SentimentPositive NewsNASDAQ:RNAZ TransCode Therapeutics (RNAZ) Stock Price, News & Analysis $1.84 +0.11 (+6.59%) As of 10:29 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsSEC Filings About TransCode Therapeutics Stock (NASDAQ:RNAZ) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get TransCode Therapeutics alerts:Sign Up Key Stats Today's Range$1.83▼$1.8350-Day Range$1.55▼$3.9652-Week Range$1.52▼$15.49Volume1,168 shsAverage Volume114,340 shsMarket Capitalization$31.22 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview TransCode Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing RNA-based medicines for the treatment of cancer, particularly metastatic disease. The company’s approach is designed to use targeted therapeutic agents to interfere with biological processes that enable cancer cells to spread. Its lead product candidate, TTX-MC138, is an investigational therapy designed to target microRNA-10b, a molecule associated with the development and progression of metastatic tumors. TransCode is evaluating the candidate as a potential treatment for multiple solid-tumor cancers and is advancing its broader RNA therapeutic platform for oncology applications. TransCode is headquartered in Boston, Massachusetts, and conducts its development activities primarily in the United States. As a development-stage biotechnology company, its products remain investigational and require further clinical testing and regulatory review before they may become commercially available.AI Generated. May Contain Errors. Read More TransCode Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks25th Percentile Overall ScoreRNAZ MarketRank™: 1.23620599054 of 5 starsTransCode Therapeutics scored higher than 25% of companies evaluated by MarketBeat, and ranked 794th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingTransCode Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageTransCode Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about TransCode Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of TransCode Therapeutics is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TransCode Therapeutics is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTransCode Therapeutics has a P/B Ratio of 0.16. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about TransCode Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.31% of the float of TransCode Therapeutics has been sold short.Short Interest Ratio / Days to CoverTransCode Therapeutics has a short interest ratio ("days to cover") of 0.76, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TransCode Therapeutics has recently decreased by 15.21%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTransCode Therapeutics does not currently pay a dividend.Dividend GrowthTransCode Therapeutics does not have a long track record of dividend growth. News and Social Media4.3 / 5News SentimentN/A News SentimentTransCode Therapeutics has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for TransCode Therapeutics this week, compared to 1 article on an average week.Search Interest3 people have searched for RNAZ on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows1 people have added TransCode Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, TransCode Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders0.10% of the stock of TransCode Therapeutics is held by insiders.Percentage Held by InstitutionsTransCode Therapeutics has minimal institutional ownership at this time.Read more about TransCode Therapeutics' insider trading history. Receive RNAZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TransCode Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RNAZ Stock News HeadlinesTransCode Therapeutics (NASDAQ:RNAZ) Stock Jumps 12.1% - Still a Buy?October 6, 2026 | americanbankingnews.comTransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-UpSeptember 28, 2026 | prnewswire.comElon's next millionaires start October 24?SpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into millionaires. One welder's $10,000 stock package made him a millionaire on IPO day. Former Wall Street CEO Dylan Jovine says Elon Musk's next venture could outsize everything he's built before. It runs on an obscure AI firm Musk has relied on since 2012, supplying crucial technology to Tesla, Starlink and SpaceX.October 16 at 1:00 AM | Behind the Markets (Ad)TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-OncologySeptember 22, 2026 | prnewswire.comTransCode Therapeutics, Inc. (RNAZ) Discusses Advancing Multi-Platform Oncology Pipeline Targeting Metastatic Cancer TranscriptSeptember 16, 2026 | seekingalpha.comJoin Today’s Live Investor Webinar with TransCode TherapeuticsSeptember 16, 2026 | usatoday.comTransCode Therapeutics Announces Leadership TransitionSeptember 10, 2026 | prnewswire.comJoin TransCode Therapeutics’ Live Investor Webinar: Advancing a Multi-Platform Oncology Pipeline Targeting Metastatic CancerSeptember 3, 2026 | usatoday.comSee More Headlines RNAZ Stock Analysis - Frequently Asked Questions How have RNAZ shares performed this year? TransCode Therapeutics' stock was trading at $6.83 at the beginning of the year. Since then, RNAZ shares have decreased by 73.6% and is now trading at $1.80. How were TransCode Therapeutics' earnings last quarter? TransCode Therapeutics Inc. (NASDAQ:RNAZ) issued its quarterly earnings data on Friday, August, 14th. The company reported ($7.17) earnings per share (EPS) for the quarter. When did TransCode Therapeutics' stock split? TransCode Therapeutics's stock reverse split on Tuesday, January 16th 2024.The 1-40 reverse split was announced on Tuesday, January 16th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did TransCode Therapeutics IPO? TransCode Therapeutics (RNAZ) raised $25 million in an initial public offering on Friday, July 9th 2021. The company issued 6,250,000 shares at $4.00 per share. How do I buy shares of TransCode Therapeutics? Shares of RNAZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of TransCode Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that TransCode Therapeutics investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Palantir Technologies (PLTR), Tesla (TSLA), Immunic (IMUX), Intel (INTC) and Micron Technology (MU). Company Calendar Last Earnings8/14/2026Today10/16/2026Next Earnings (Estimated)11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 RNAZ's financial health is in the Yellow zone, according to TradeSmith. RNAZ has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RNAZ CIK1829635 Webwww.transcodetherapeutics.com Phone(857) 301-6857FaxN/AEmployees12Year FoundedN/AProfitability EPS (Trailing Twelve Months)($52.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$34.66 million Net MarginsN/A Pretax MarginN/A Return on Equity-875.35% Return on Assets-37.46% Debt Debt-to-Equity RatioN/A Current Ratio1.97 Quick Ratio1.97 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$11.27 per share Price / Book0.16Miscellaneous Outstanding Shares16,931,000Free Float16,914,000Market Cap$30.98 million OptionableNot Optionable Beta1.25 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:RNAZ) was last updated on 10/16/2026 by MarketBeat.com Staff. From Our PartnersA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | SponsoredMy next big call (under $1)Bitcoin is down. Fear is high. Most investors are sitting on their hands. That's exactly when my biggest winne...Crypto 101 Media | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredElon says the ‘S’ wordElon Musk and Sam Altman have sued each other and feuded for years. Yet within days of one another, both men d...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransCode Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransCode Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
